Pharmaceutical News and Articles

Comprehensive and up-to-date drug news for both consumers and healthcare professionals.

1 in 3 Older Americans Say They Feel Lonely, Poll Finds

If you are middle-aged or older, you may often feel lonely and isolated as you deal with the strains of daily life. Now, a new survey suggests you are far from

Dolphins Are Testing Positive for Fentanyl

Most Americans understand how deeply the dangerous opioid fentanyl has permeated the illicit drug market. Now, it s even infiltrated the bodies of Gulf of Mexic

There's a 'Sweet Spot' for Daily Sugar Intake & Heart Health

When it comes to sweets, the type a person chooses can have a significant impact on their heart health, a new study finds. Sugary drinks significantly increase

Global Warming's Heat Is Killing the World's Young

Heat waves caused by climate change have been thought to pose the greatest risk to the world s elderly, but a new study from Mexico suggests that s not the case

EPA Bans Two Solvents Linked to Cancer

Two commonly used solvents that have been linked to cancer were banned Monday by the Environmental Protection Agency. The solvents, known as trichloroethylene (

Trump Says RFK Jr. Free to Revisit Discredited Autism/Vaccine Link

If Robert F. Kennedy Jr. is approved to head the U.S. Department of Health and Human Services, he will be free to revisit a long-debunked link between autism an

Rilzabrutinib Demonstrated Significant Patient Benefit in the First Positive Phase 3 Study of a BTK Inhibitor in ITP

Paris, December 7, 2024. Positive results from the pivotal LUNA 3 phase 3 study of rilzabrutinib in adults with persistent or chronic immune thrombocytopenia (I

Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab

Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) today announced positive updated Phase 3 data of an exploratory cohort from the ACCESS-1 trial investigating its f

Phase 2 Data From the Ongoing Hibiscus Study Shows Promise That Investigational Etavopivat Could Reduce the Incidence of Vaso-occlusive Crises in People With Sickle Cell Disease

Novo Nordisk today announced 52-week results from the phase 2 part of the ongoing phase 2 3 HIBISCUS study program of investigational etavopivat in people with

Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

Merck (NYSE MRK), known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial evalu

Popular Keywords